The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer
美國食品藥品管理局已接受葛蘭素史克的Jemperli（Dostarlimab）與標準護理化療聯合的補充生物製劑許可申請，將治療範圍擴大到所有原發性晚期或複發性子宮內膜癌的成年患者